eFFECTOR Therapeutics, Inc. Common Stock
EFTR
EFTR was delisted on the 2nd of July, 2024.
18 hedge funds and large institutions have $174M invested in eFFECTOR Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 5 closing their positions.
120% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 5
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
50% more funds holding
Funds holding: 12 → 18 (+6)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
7% less capital invested
Capital invested by funds: $188M → $174M (-$13.8M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.79M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$667K |
| 3 |
AA
ALPS Advisors
Denver,
Colorado
|
+$482K |
| 4 |
Morgan Stanley
New York
|
+$265K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$155K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.64M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
-$347K |
| 3 |
Jane Street
New York
|
-$257K |
| 4 |
VF
Virtu Financial
New York
|
-$245K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$187K |
EFTR Hedge Fund Activity: Q4 2021 in Review
18 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in eFFECTOR Therapeutics, Inc. Common Stock (EFTR) for Q4 2021, worth a combined $174M — down 7.3% from $188M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new EFTR positions and 5 closed out — a net gain of 6 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $4.79M. The largest seller was Sectoral Asset Management, cutting an estimated $4.64M.
- 18 institutional investors held eFFECTOR Therapeutics, Inc. Common Stock (EFTR) as of Q4 2021, up from 12 in Q3 2021.
- Funds reported $174M of eFFECTOR Therapeutics, Inc. Common Stock stock for Q4 2021, down 7.3% quarter-over-quarter.
- 11 funds opened new eFFECTOR Therapeutics, Inc. Common Stock positions in Q4 2021 and 5 closed out, a net change of +6 holders.
- The largest eFFECTOR Therapeutics, Inc. Common Stock buyer in Q4 2021 was Vanguard Group, an estimated $4.79M added.
- The largest eFFECTOR Therapeutics, Inc. Common Stock seller in Q4 2021 was Sectoral Asset Management, an estimated $4.64M sold.
Based on aggregated 13F filings for Q4 2021.